Epizootic hemorrhagic disease (EHD) is an important disease that severely affects wild and domestic ruminants, and causes substantial economic losses in the livestock industry. The etiological agent, epizootic hemorrhagic disease virus (EHDV), is an arbovirus of the genus Orbivirus. The virus is transmitted through infected Culicoides midges biting susceptible hosts. EHDV has a worldwide distribution, and recently, it has expanded to Europe from 2022. To date, seven different EHDV serotypes have been described and no effective DIVA (Differentiating Infected from Vaccinated Animals) vaccines against EHDV are available. The aim of our research is to explore vaccine candidates expressing a single EHDV antigen to develop an efficient marker and safe vaccine candidate. Recombinant Modified Vaccinia Ankara virus (MVA) viral vector vaccines are effective, safe, and DIVA-compatible candidates against EHDV. In this study, we designed and generated novel vaccine candidates against EHDV based on recombinant MVAs that express the non-structural protein NS1 from EHDV serotype 8. The potential vaccine was evaluated in IFNAR (-/-) mice, which are susceptible to EHDV infection and reproduce certain features of EHDV infection in natural hosts. IFNAR (-/-) mice were immunized with two doses of MVA-NS1 and subsequently challenged with EHDV-8 or EHDV-6. Immunized mice did not show viremia or clinical signs after EHDV-8 challenge, and showed reduced RNAemia titers against the virus. Therefore, vaccinated mice were completely protected against a homologous challenge with EHDV-8 after two doses of the vaccine candidate. MVA-NS1 did not confer complete protection against a heterologous challenge with EHDV-6, although it delayed the onset of clinical signs and death. These data show that the MVA-NS1 vaccine candidate is safe and efficient against a homologous challenge and compatible with a DIVA strategy.